Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

被引：101

作者：

Kaiser, Christina ^{[1
]}

Knight, Ann ^{[2
]}

Nordstrom, Dan ^{[3
]}

Pettersson, Tom ^{[3
]}

Fransson, Jonas ^{[1
]}

Florin-Robertsson, Ebba ^{[1
]}

Pilstrom, Bjorn ^{[1
]}

机构：

[1] Swedish Orphan Biovitrum AB, S-11276 Stockholm, Sweden

[2] Univ Uppsala Hosp, Dept Rheumatol, S-75185 Uppsala, Sweden

[3] Univ Helsinki, Cent Hosp, Div Rheumatol & Internal Med, FIN-00290 Helsinki, Finland

来源：

RHEUMATOLOGY INTERNATIONAL | 2012年 / 32卷 / 02期

关键词：

Anakinra; Kineret; Injection-site reactions; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ACTIVE RHEUMATOID-ARTHRITIS; PLACEBO-CONTROLLED TRIAL; SUBCUTANEOUS INJECTIONS; DOUBLE-BLIND; SAFETY; METHOTREXATE; DISEASE; MULTICENTER; DRUGS;

D O I：

10.1007/s00296-011-2096-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.

引用

页码：295 / 299

页数：5

共 30 条

[1] Physiologic role of interleukin-1 receptor antagonist [J].

Arend, WP ;

Gabay, C .

ARTHRITIS RESEARCH, 2000, 2 (04) :245-248

[2]

Assanasen Paraya, 2002, Clin Allergy Immunol, V17, P101

[3]

BENDELE A, 1995, J LAB CLIN MED, V125, P493

[4]

Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO

[5]

2-U

[6]

Clarke JB, HDB EXP PHARM, P453

[7] Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [J].

Cohen, S ;

Hurd, E ;

Cush, J ;

Schiff, M ;

Weinblatt, ME ;

Moreland, LW ;

Kremer, J ;

Bear, MB ;

Rich, WJ ;

McCabe, D .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :614-624

[8] A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J].

Cohen, SB ;

Moreland, LW ;

Cush, JJ ;

Greenwald, MW ;

Block, S ;

Shergy, WJ ;

Hanrahan, PS ;

Khraishi, MM ;

Patel, A ;

Sun, G ;

Bear, MB .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1062-1068

[9] Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice [J].

den Broeder, A. A. ;

de Jong, E. ;

Franssen, M. J. A. M. ;

Jeurissen, M. E. C. ;

Flendrie, M. ;

van den Hoogen, F. H. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) :760-762

[10] Safety of extended treatment with anakinra in patients with rheumatoid arthritis [J].

Fleischmann, R. M. ;

Tesser, J. ;

Schiff, M. H. ;

Schechtman, J. ;

Burmester, G-R ;

Bennett, R. ;

Modafferi, D. ;

Zhou, L. ;

Bell, D. ;

Appleton, B. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) :1006-1012

← 1 2 3 →